Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
$5.48
-$0.17(-3.14%)
At close: 4:00 PM EST
$5.48
-$0.17(-3.14%)
Day’s Range― - ―
52-Week Range$3.21 - $8.40
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.97M
Market Cap
$1.34B
Enterprise Value$1.49B
Total Cash (Recent Filing)$264.69M
Total Debt (Recent Filing)$211.59M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Apr 30, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding245,247,420
10 Day Avg. Volume3,522,050
30 Day Avg. Volume3,965,269
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)8.42
Price to Sales (P/S)3.45
P/FCF Ratio-31.96
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue3.65
Enterprise Value/Gross Profit4.04
Enterprise Value/Ebitda-50.99
Forecast
1Y Price Target
$16.38Price Target Upside198.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.02
Revenue Forecast (FY)$550.07M
Bulls Say, Bears Say
Bulls Say
Commercial Execution And Prescription TrendsRising prescription trends and deeper commercial penetration for Ibsrela, together with investments in salesforce and patient support, indicate improving prescription pull-through that supports higher future sales expectations.
Label Expansion And Clinical DevelopmentInitiation of a Phase 3 study to evaluate Ibsrela for chronic idiopathic constipation could broaden the drug's approved use into a substantially larger patient population, increasing the addressable market and upside for sales.
Patent ProtectionA newly allowed U.S. formulation patent listed in the FDA Orange Book could extend exclusivity for Ibsrela and Xphozah, strengthening long-term revenue prospects if patent protection holds up under legal review.
Bears Say
Execution Risk And Adoption UncertaintyUncertainty remains whether growth initiatives and commercial investments will drive sufficient adoption to meet ambitious targets, creating execution risk that could temper revenue outcomes.
Medicare Access LimitationsManagement's expectation that Xphozah will not be re-included in Medicare Part D may limit uptake among Medicare beneficiaries and constrain revenue potential for that product.
Regulatory And Legal VulnerabilityRegulatory hurdles and the potential need for additional legal clarity around the new patent create downside risk if exclusivity is narrowed or if further regulatory requirements delay commercialization plans.
Ardelyx News
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.21 and its highest was $8.40 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.34B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Apr 30, 2026 which is in 31 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Feb 19, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.013 by -$0.013.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -0.13.
How many shares outstanding does Ardelyx have?
Ardelyx has 245,247,420 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of $0 in its last earnings report, missing expectations of $0.013. Following the earnings report the stock price went down -14.985%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.38 (198.91% Upside)
$16.38 (198.91% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 350.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
-40.63%
Trailing 12-Months
Asset Growth
15.39%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Company Deck
ARDX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum driven by IBSRELA (73% revenue growth in 2025), meaningful revenue guidance and a strengthened pipeline (Phase III CIC trial and next-gen NHE3), supported by improved cash and a new Orange Book-listed formulation patent. Counterbalancing that are a sizable decline in XPHOZAH revenue due to Medicare reimbursement changes, materially higher SG&A/R&D spending and a wider net loss. Management is investing to scale IBSRELA and advance pipeline programs and expects these investments to drive outsized revenue growth versus expense growth over time.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$16.38
▲(198.91% Upside)
Technical Analysis
Vericel
―
Viridian Therapeutics
―
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Ownership Overview
3.74% Insiders
23.26% Mutual Funds
9.93% Other Institutional Investors
49.71% Public Companies and
Individual Investors